Phase 4 Atrial Fibrillation Trial, RecruitingNCT03968393Sponsor: Population Health Research InstituteCondition: Atrial Fibrillation
Printed from Voxsanity (voxsanity.com.au) — NCT03968393 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.
AI generated eligibility summary.
Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source.
How we use AI
Who might be able to join this trial:
People who had at least one episode of atrial fibrillation (an irregular heart rhythm) that occurred during or after a non-heart-related surgery or a serious illness requiring a hospital stay within the past 35 days
People whose heart is beating in a normal, regular rhythm at the time they would enter the trial
People who meet certain age and health risk combinations — for example, those aged 55–64 with heart or blood vessel disease or other risk factors, those aged 65–74 with similar risk factors, or those aged 75 and older (confirm specific details with trial site)
People who are able and willing to give written consent to participate
Who may not be able to join:
People whose main reason for being admitted to hospital was a heart condition
People who have a history of long-term or ongoing atrial fibrillation diagnosed before their surgery
People who already need to take long-term blood-thinning (anticoagulant) medication
People who already need to take two different types of blood-thinning (antiplatelet) medications long-term at the same time
People for whom blood-thinning medication would be considered unsafe or unsuitable
People with severely reduced kidney function
People with severe liver disease (the most serious stage of liver scarring)
People who have had a stroke within the past 14 days
People who had heart surgery within the past 35 days
People who have a history of bleeding inside the skull, eye, or spine that was not caused by an injury
People with a condition that causes problems with blood clotting or abnormal bleeding
People who are unlikely to be able to attend follow-up visits or take the study medications as required
People whose life expectancy is less than one year due to another serious illness
Women who are pregnant, breastfeeding, or capable of becoming pregnant and not using effective contraception
People who have already taken part in this trial previously
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 21 July 2026
Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
Contact this trial
Principal Investigator: David Conen, MD, MPH, Population Health Research Institute
Canberra Hospital, Garran, Australian Capital Territory
Bankstown Hospital, Bankstown, New South Wales
Royal Prince Alfred Hospital, Camperdown, New South Wales
Concord Repatriation General Hospital, Concord, New South Wales
Liverpool Hospital, Liverpool, New South Wales
John Hunter Hospital, Newcastle, New South Wales
Westmead Hospital, Westmead, New South Wales
Sunshine Coast Hospital and Health Service, Birtinya, Queensland
Royal Brisbane and Women's Hospital, Herston, Queensland
Redcliffe Hospital, Redcliffe, Queensland
Royal Adelaide Hospital, Adelaide, South Australia
Box Hill Hospital, Box Hill, Victoria
Northeast Health Wangaratta, Wangaratta, Victoria
Royal Perth Hospital, Perth, Western Australia
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Voxsanity
Clinical trials and treatments, explained plainly · voxsanity.com.au
Date:
To: My Doctor
Re: Clinical trial enquiry
I am writing to enquire about the following clinical trial which may be relevant to my care:
Trial: NCT03968393
Sponsor: Population Health Research Institute
Phase: Phase 4
Status: Recruiting
Condition: Atrial Fibrillation
Trial contact: 1-905-594-0560
More information: https://clinicaltrials.gov/study/NCT03968393
Eligibility summary (AI generated)
Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.
Who might be able to join this trial:
People who had at least one episode of atrial fibrillation (an irregular heart rhythm) that occurred during or after a non-heart-related surgery or a serious illness requiring a hospital stay within the past 35 days
People whose heart is beating in a normal, regular rhythm at the time they would enter the trial
People who meet certain age and health risk combinations — for example, those aged 55–64 with heart or blood vessel disease or other risk factors, those aged 65–74 with similar risk factors, or those aged 75 and older (confirm specific details with trial site)
People who are able and willing to give written consent to participate
Who may not be able to join:
People whose main reason for being admitted to hospital was a heart condition
People who have a history of long-term or ongoing atrial fibrillation diagnosed before their surgery
People who already need to take long-term blood-thinning (anticoagulant) medication
People who already need to take two different types of blood-thinning (antiplatelet) medications long-term at the same time
People for whom blood-thinning medication would be considered unsafe or unsuitable
People with severely reduced kidney function
People with severe liver disease (the most serious stage of liver scarring)
People who have had a stroke within the past 14 days
People who had heart surgery within the past 35 days
People who have a history of bleeding inside the skull, eye, or spine that was not caused by an injury
People with a condition that causes problems with blood clotting or abnormal bleeding
People who are unlikely to be able to attend follow-up visits or take the study medications as required
People whose life expectancy is less than one year due to another serious illness
Women who are pregnant, breastfeeding, or capable of becoming pregnant and not using effective contraception
People who have already taken part in this trial previously
Important: Always verify eligibility with the trial site directly before applying.
Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.
This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 21 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.
Trial details
Status
Recruiting
Phase
Phase 4
Sponsor
Population Health Research Institute
Registry
ClinicalTrials.gov
Start date
14 June 2019
Est. completion
1 December 2028
Where this trial is recruiting
🇦🇷 Argentina
🇦🇺 Australia
🇧🇷 Brazil
🇨🇦 Canada
🇩🇰 Denmark
🇫🇮 Finland
🇩🇪 Germany
🇮🇳 India
🇮🇹 Italy
Nepal
🇳🇱 Netherlands
🇵🇰 Pakistan
🇰🇷 South Korea
🇪🇸 Spain
🇸🇪 Sweden
🇨🇭 Switzerland
🇬🇧 United Kingdom
🇺🇸 United States
14 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Incidence of Non-hemorrhagic stroke or systemic embolism; Incidence of vascular mortality, and non-fatal non-hemorrhagic stroke, myocardial infarction, peripheral arterial thrombosis, amputation, and symptomatic venous thromboembolism
Can't join this trial?
Expanded access pathways
If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.
Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.
Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.